ArticleSurgery2026
Sprayable pH-sensitive near-infrared fluorophore for rapid, bright, specific, and safe visualization of human thyroid cancer in orthotopic mouse models.
Article in Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Rapid Ex Vivo Visualization of Laryngeal Tumors Using a Sprayable pH-Activatable Fluorophore.Molecular diagnosis & therapy · 2026Article
- Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer.Cancers · 2026Review
- Real-Time Detection of Colorectal Cancer Using Topical Application of a pH-Activatable Fluorophore.Molecular diagnosis & therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSurgery is the primary treatment for thyroid cancer. However, incomplete resection of thyroid cancer can result in local, regional, and distant recurrences that are life threatening. We hypothesized that a topically applied, pH-sensitive near-infrared fluorophore in spray form (PH10) could offer rapid labeling of thyroid tumors, enabling better visualizion of the tumor and its margins.
methodsCellar uptake inhibition and cytotoxicity studies using PH10 were performed on TPC-1 papillary and TT medullary thyroid cancer cells. Subcutaneous or orthotopic tumors were established by injecting TPC-1 cells in the flanks or thyroid glands of nude mice, respectively, and sprayed with PH10. Fluorescence of the tumor was compared to surrounding tissues. Tumors were harvested for pathologic analysis.
resultsThe organic anion transporter peptide mediated uptake of PH10 in TPC-1 and TT cells was determined. PH10 exhibited an IC50 value of 13.18 and 17.28 μM in TPC-1 and TT cells, respectively. Both subcutaneous and orthotopic tumors displayed strong near-infrared fluorescence upon spraying PH10 at a concentration of 10 μM on the tumor sites, within 1 minute, contrasting with surrounding tissues. The effective PH10 dose for tumor visualization was well below the IC50. The average tumor to background ratios were 5.5 (±1.47) for subcutaneous tumors (n = 5) and 9.4 (±2.59) for orthotopic tumors (n = 5). Hematoxylin and eosin staining confirmed the tumor characteristics.
conclusionThe pH-sensitive near-infrared fluorophore PH10 brightly, rapidly, specifically, and safely labeled thyroid cancer in mouse models by spraying, demonstrating future clinical promise as a useful agent for improved visualization of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.